Do analysts recommend PTPI or CNSP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PTPI or CNSP more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% CNS Pharmaceuticals N/A -204.25% -141.87%

Do analysts recommend CNSP or CPHI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate CNSP or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CNSP or ABVC more profitable?

ABVC BioPharma's return on equity of -47.68% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -204.25% -141.87% ABVC BioPharma N/A -47.68% -30.97%

Do analysts prefer CNSP or OPTH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is CNSP or OPTH more profitable?

Optimi Health's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -204.25% -141.87% Optimi Health N/A N/A N/A

Do analysts rate LONA or CNSP?

Athira Pharma presently has a consensus target price of $17.33, indicating a potential upside of 259.61%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than CNS Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, LONA or CNSP?

Athira Pharma is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$4.21 N/A CNS Pharmaceuticals N/A N/A -$15.85M -$23.59 N/A

Is LONA or CNSP more profitable?

CNS Pharmaceuticals' return on equity of -204.25% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% CNS Pharmaceuticals N/A -204.25% -141.87%

CNS Pharmaceuticals (CNSP) Competitors

$5.32 +0.08 (+1.53%)

Closing price 10/2/2026 03:58 PM Eastern

Extended Trading

$5.47 +0.15 (+2.78%)

As of 10/2/2026 08:00 PM Eastern

Compare

CNSP vs. PTPI, CPHI, ABVC, OPTH, and LONA

Should you buy CNS Pharmaceuticals stock or one of its competitors? CNS Pharmaceuticals's main competitors and comparable companies include Petros Pharmaceuticals (PTPI), China Pharma (CPHI), ABVC BioPharma (ABVC), Optimi Health (OPTH), and Athira Pharma (LONA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

In the previous week, Petros Pharmaceuticals had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for Petros Pharmaceuticals and 0 mentions for CNS Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
CNS Pharmaceuticals	Neutral

Petros Pharmaceuticals has a beta of 1.87, indicating that its stock price is 87% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.1, indicating that its stock price is 210% more volatile than the broader market.

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$0.36	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to China Pharma?

CNS Pharmaceuticals (NASDAQ:CNSP) and China Pharma (NYSE:CPHI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

China Pharma has higher revenue and earnings than CNS Pharmaceuticals. China Pharma is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
China Pharma	$3.91M	7.22	-$3.08M	-$0.43	N/A

CNS Pharmaceuticals has a beta of 3.1, indicating that its share price is 210% more volatile than the broader market. Comparatively, China Pharma has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

14.0% of CNS Pharmaceuticals shares are held by institutional investors. 1.8% of CNS Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of China Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, China Pharma had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for China Pharma and 0 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.00 equaled China Pharma'saverage media sentiment score.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
China Pharma	Neutral

CNS Pharmaceuticals has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
China Pharma	-85.56%	-63.93%	-31.42%

Summary

China Pharma beats CNS Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to ABVC BioPharma?

CNS Pharmaceuticals (NASDAQ:CNSP) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

ABVC BioPharma's return on equity of -47.68% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
ABVC BioPharma	N/A	-47.68%	-30.97%

CNS Pharmaceuticals has a beta of 3.1, indicating that its share price is 210% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 1.8% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma has higher revenue and earnings than CNS Pharmaceuticals. ABVC BioPharma is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
ABVC BioPharma	$510K	52.86	-$7.91M	-$0.30	N/A

In the previous week, ABVC BioPharma had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for ABVC BioPharma and 0 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.00 equaled ABVC BioPharma'saverage media sentiment score.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
ABVC BioPharma	Neutral

Summary

ABVC BioPharma beats CNS Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Optimi Health?

CNS Pharmaceuticals (NASDAQ:CNSP) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

In the previous week, Optimi Health had 3 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 3 mentions for Optimi Health and 0 mentions for CNS Pharmaceuticals. Optimi Health's average media sentiment score of 0.99 beat CNS Pharmaceuticals' score of 0.00 indicating that Optimi Health is being referred to more favorably in the news media.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
Optimi Health	Positive

Optimi Health's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
Optimi Health	N/A	N/A	N/A

Optimi Health has higher revenue and earnings than CNS Pharmaceuticals. Optimi Health is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
Optimi Health	$310K	82.99	-$1.12M	-$0.76	N/A

14.0% of CNS Pharmaceuticals shares are held by institutional investors. 1.8% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Optimi Health beats CNS Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Athira Pharma had 2 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 2 mentions for Athira Pharma and 0 mentions for CNS Pharmaceuticals. Athira Pharma's average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Athira Pharma	Neutral
CNS Pharmaceuticals	Neutral

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 1.8% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Athira Pharma is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A

CNS Pharmaceuticals' return on equity of -204.25% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

Athira Pharma has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.1, indicating that its stock price is 210% more volatile than the broader market.

Athira Pharma presently has a consensus target price of $17.33, indicating a potential upside of 259.61%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Athira Pharma beats CNS Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNSP vs. The Competition

Export

Metric	CNS Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.78M	$12.27B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	-0.23	802.26	276.26	26.04
Price / Sales	N/A	940.01	656.47	105.14
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	0.73	10.52	10.93	6.31
Net Income	-$15.85M	$2.86B	$3.51B	$362.16M
7 Day Performance	5.45%	-1.58%	-2.00%	-1.66%
1 Month Performance	-8.13%	-5.55%	-6.19%	-4.68%
1 Year Performance	-40.56%	-2.19%	8.03%	1.57%

CNS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNSP CNS Pharmaceuticals	0.2057 of 5 stars	$5.32 +1.5%	N/A	-40.6%	$7.78M	N/A	N/A	8	High Trading Volume
PTPI Petros Pharmaceuticals	N/A	$0.00 +15.0%	N/A	-84.6%	$143K	$5.11M	N/A	20	Gap Up
CPHI China Pharma	N/A	$0.66 -8.0%	N/A	-65.2%	$28.31M	$3.91M	N/A	221	News Coverage
ABVC ABVC BioPharma	0.335 of 5 stars	$1.04 -1.0%	N/A	-66.3%	$27.99M	N/A	N/A	19
OPTH Optimi Health	0.6426 of 5 stars	$4.78 -1.4%	N/A	N/A	$27.77M	$310K	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNSP) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, CPHI, ABVC, OPTH, and LONA

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Summary

How does CNS Pharmaceuticals compare to China Pharma?

Summary

How does CNS Pharmaceuticals compare to ABVC BioPharma?

Summary

How does CNS Pharmaceuticals compare to Optimi Health?

Summary

How does CNS Pharmaceuticals compare to Athira Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, CPHI, ABVC, OPTH, and LONA

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Does the media favor PTPI or CNSP?

Which has more risk & volatility, PTPI or CNSP?

Is PTPI or CNSP more profitable?

Do analysts recommend PTPI or CNSP?

Which has higher valuation & earnings, PTPI or CNSP?

Do insiders & institutionals believe in PTPI or CNSP?

Summary

How does CNS Pharmaceuticals compare to China Pharma?

Which has stronger valuation & earnings, CNSP or CPHI?

Which has more risk and volatility, CNSP or CPHI?

Do insiders and institutionals hold more shares of CNSP or CPHI?

Do analysts recommend CNSP or CPHI?

Does the media favor CNSP or CPHI?

Is CNSP or CPHI more profitable?

Summary

How does CNS Pharmaceuticals compare to ABVC BioPharma?

Is CNSP or ABVC more profitable?

Which has more volatility & risk, CNSP or ABVC?

Do insiders & institutionals hold more shares of CNSP or ABVC?

Do analysts rate CNSP or ABVC?

Which has higher earnings & valuation, CNSP or ABVC?

Does the media refer more to CNSP or ABVC?

Summary

How does CNS Pharmaceuticals compare to Optimi Health?

Does the media refer more to CNSP or OPTH?

Is CNSP or OPTH more profitable?

Which has higher valuation and earnings, CNSP or OPTH?

Do institutionals and insiders hold more shares of CNSP or OPTH?

Do analysts prefer CNSP or OPTH?

Summary

How does CNS Pharmaceuticals compare to Athira Pharma?

Does the media refer more to LONA or CNSP?

Do institutionals & insiders believe in LONA or CNSP?

Which has stronger valuation and earnings, LONA or CNSP?

Is LONA or CNSP more profitable?

Which has more risk & volatility, LONA or CNSP?

Do analysts rate LONA or CNSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools